Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $3.6 million.

  • Altimmune's Share-based Compensation rose 1546.46% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.5 million, marking a year-over-year increase of 726.24%. This contributed to the annual value of $14.4 million for FY2024, which is 3527.26% up from last year.
  • As of Q3 2025, Altimmune's Share-based Compensation stood at $3.6 million, which was up 1546.46% from $3.6 million recorded in Q2 2025.
  • Altimmune's Share-based Compensation's 5-year high stood at $4.3 million during Q2 2024, with a 5-year trough of $1.2 million in Q1 2021.
  • Its 5-year average for Share-based Compensation is $2.6 million, with a median of $2.7 million in 2023.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 46671.99% in 2021, then tumbled by 1728.14% in 2025.
  • Quarter analysis of 5 years shows Altimmune's Share-based Compensation stood at $1.3 million in 2021, then surged by 43.44% to $1.9 million in 2022, then surged by 30.5% to $2.5 million in 2023, then skyrocketed by 35.84% to $3.4 million in 2024, then grew by 5.96% to $3.6 million in 2025.
  • Its Share-based Compensation stands at $3.6 million for Q3 2025, versus $3.6 million for Q2 2025 and $4.0 million for Q1 2025.